Anbio Biotechnology is making significant inroads into the European healthcare industry with its flagship product, the AF-100 C, a sophisticated compact fluorescent immunoassay analyzer designed to transform the landscape of point-of-care diagnostics. Capable of executing over 70 assays, the AF-100 C is set to significantly bolster healthcare services across the EU, improving both patient care and diagnostic outcomes.
Anbio Biotechnology (Anbio), a vanguard in vitro diagnostics, is proud to present its extensive “Point of Care” product range to the European Union. This strategic move marks a pivotal moment for Anbio, fostering partnerships with EU distributors and healthcare providers, and highlighting the company’s commitment to equipping the European healthcare market with avant-garde diagnostic solutions.
Anbio stands out for its commitment to innovation and its diverse product portfolio, which extends beyond mere Covid testing kits. “Our mission is to revolutionize diagnostics by offering tailored and accessible solutions, including laboratory, wellness, at-home, and point-of-care diagnostics. We are committed to affordability and continuous innovation in life sciences that serve to advance human heath,” declared Michael Lau, Anbio’s Chief Executive Officer.
Leading-Edge Analyzer with Extensive Test Capabilities
The focal point of Anbio’s launch in the EU is the AF-100 C analyzer, an advanced, portable, rechargeable compact fluorescent Immunoassay (FIA) analyzer. This device, coupled with over 70 CE marked assays for a variety of analytes, is poised to redefine clinical diagnostics across the continent.
“The Anbio AF-100 C is a game-changer for clinical diagnostics, supplying healthcare providers with a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing,” Lau said. Despite its small size, the AF-100 C offers high throughput and is ideally suited for a range of clinical environments, ensuring that healthcare professionals can provide superior patient care with greater efficiency.
Revolutionising Healthcare with Fast, Precise Diagnostics
Anbio’s FIA test range, which delivers results in just 3 to 15 minutes, represents a significant advancement in diagnostic technology. With reagents that use RFID chip technology for enhanced accuracy and can be stored at room temperature for up to 24 months, Anbio is well-equipped to meet the immediate needs of Europe’s healthcare sector.
As Anbio Biotechnology introduces itself to the European market, it welcomes distributors and healthcare practitioners to explore its state-of-the-art diagnostic solutions. Dedicated to improving patient care through affordable, precise, and reliable diagnostics, Anbio is keen to form partnerships with healthcare entities across the EU.
